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Structure, Function and Inhibition of Poly(ADP-ribose)polymerase, 
member 14 (PARP14). 
 
Stephanie S. Schweiker*a, Amanda L. Taubera, Madeleine E. Sherrya and Stephan M. Levonisa 
a Medicinal Chemistry Group, Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Australia; 
*sschweik@bond.edu.au 
Abstract: Poly(ADP-ribose)polymerase, member 14 (PARP14, alternatively named ARTD8, BAL2, and COAST6) is an intracellular 
mono(ADP-ribosyl) transferase. PARP14 transfers a negatively charged ADP-ribose unit from a donor NAD+ molecule onto a target protein, 
post-translationally. PARP14’s domain architecture consists of three macrodomains (Macro1, Macro2 and Macro3), a WWE domain and an 
ARTD (or catalytic domain). The Macro2 and Macro3 domains bind ADP-ribose (ADPr) with high affinity, whereas the WWE domain 
stabilizes the protein structure by binding to ADPr derivatives. The catalytic domain is involved in binding the NAD+ and catalyzing the mono-
ADP-ribosylation reaction. PARP14 has been identified as a possible anti-cancer and anti-inflammatory target. Acting as a transcriptional co-
activator for STAT6, PARP14 acts to promote the over activation of the Th2 immune response, thus promoting the metabolic change to an 
anaerobic state (Warburg effect) and activation of cell survival pathways through JNK2 and the PGI/AMF complex. These changes are 
consistent with the metabolic sophistication observed in cancer, and the immune imbalance in inflammatory diseases. Current literature on 
selective and unselective PARP14 inhibitors are reviewed and discussed. Although there is no evidence that selective PARP inhibitors would 
be advantageous we have proposed some strategies for future design of selective PARP14 inhibitors. 
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1. INTRODUCTION 
1.1. The PARP superfamily   
 The Poly(ADP-ribose) polymerase (PARP) family 
consists of 18 genes which encode 17 intracellular ADP-
ribose transferase enzymes (ARTDs) [1]. PARP enzymes 
post-translationally transfer negatively charged ADP-ribose 
groups from donor NAD+ molecules onto their target proteins. 
The transfer reaction is facilitated by the highly conserved 
catalytic domain within all members of the superfamily [1]. 
PARPs contain a donor loop (D-loop) and acceptor loop in 
their catalytic site for stabilizing ligand bonds and 
strengthening ties with nearby PARPs [2]. Through 
poly(ADP-ribosyl)ation (PARylation) of the target protein 
PARPs control a wide array of biochemical processes. 
PARylation is especially prevalent during transcription 
regulation, stress responses, DNA repair, RNA interface, 
mitochondrial function, cell division and formation of sub-
nuclear bodies [3]. 
The superfamily of PARP proteins was originally identified 
from the homology of PARP1, with most now having readily 
available crystal structures online through The Protein Data 
Bank (Table 1) [1, 4]. ARTDs nomenclature has been 
proposed for the PARPs since not all PARPs are 
enzymatically active and some function as mono(ADP-
ribosyl) transferases (MARs) rather than Poly(ADP-ribose) 
polymerase (PARs) (Table 1) [5]. The PARP superfamily can 
be subcategorised into: DNA-dependent PARPs (PARP1, 
PARP2 and PARP3); tankyrases (PARP5A, and PARP5B); 
the CCCH (Cys-Cys-Cys-His) PARPs (PARP7, PARP12, and 
PARP13); and the macroPARPs (PARP9, PARP14 and 
PARP15). The other five PARPs (PARP4, PARP6, PARP8, 
PARP10, PARP11 and PARP16) have distinct domain 
structures and are not part of a subfamily [1, 3]. 
 
1.2 PARylation and MARylation 
PARs of the PARP superfamily create polymers of branched 
or elongated (linear) ADP-ribose (ADPr) residues by their 
transfer reaction [6]. The polymerization event is promoted by 
the H-Y-E motif, located within the catalytic domain of 
PARP1-5a/b (PAR-generating) [7]. These members use the 
glutamate residue (E988) in their catalytic domain to assist 
with the transfer of numerous ribose units, and the eventual 
elongation of the target protein [7]. During PARylation of 
PARPs with a target protein, the PARP uses one NAD+ as a 
donor ADPr unit to generate one ADPr and one nicotinamide. 
The cleaved ADPr is then attached to the Lys residue or the 
carboxylic acid of the Glu or Asp on the target protein [3]. The 
protein modifications are accelerated by the histidine and 
tyrosine of the motif, which guide NAD+ into close proximity 
with the PARP catalytic domain [7]. The elongation reaction 
proceeds when the adenine-proximal ribose (A-ribose) units 
from the PAR chain termini are joined to an α(12) O-
glycosidic bond. The branching reaction occurs between two 
nicotinamide-proximal ribose (N-ribose) rings [3]. The 
specific structure of the PARs is thought to inhibit apoptotic 
pathways under stressful or hypoxic events [8]. The stress 
leads to synthesis of PAR-generating PARPs that contain 
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molecular material for the inhibition of mitogen activated 
protein kinases (MAPK), and further, the inhibition of 
apoptosis in dependent cells [8]. MAPK pathway inhibition is 
a target for cancer therapy in cancer cell lines that rely upon 
PARs function [8].  
MARs are a subfamily of PARPs that share the highly 
conserved catalytic domain, however, lack the glutamate 
residue at position 988 [1]. In place of glutamate, MARs hold 
an isoleucine, leucine or valine. The subtle difference in the 
MARs subfamily does not allow the enzyme to form linear or 
branched chain polymers [1]. Instead, MARs are capable of 
MARylation [2]. MARs activity has been linked to the 
Unfolded Protein Response (UPR), and signal transduction 
[1]. UPR involves upregulation of MARs and is a protective 
measure of a cell under high cellular demand [1]. Exhaustive 
UPR is a hallmark of cancer, as cell apoptosis may be avoided 
[7]. However, the investigation into the structure and function 
relationship of MARs, PARP14 inclusive, has not been 
extensive [7].  
Table 1: PARP superfamily members classifications and functions.  
Subclass PARP 
family 
member 
Alternative 
names 
Enzymatic 
activity 
Key functional domains Crystal Structure (.pdb) 
DNA-
dependent 
PARP1  
 
PARP2  
PARP3  
ARTD1 
 
ARTD2 
ARTD3 
PAR  
 
PAR  
PAR  
ARTD, WGR, Zinc Fingers and 
BRCT. 
ARTD and WGR 
ARTD and WGR 
YES 
 
YES 
YES 
CCCH 
PARP 
PARP7  
 
PARP12  
 
PARP13  
 
ARTD14, 
TIPARP, 
RM1 
ARTD12, 
ZC3HDC1 
ARTD13, 
ZC3HAV1, 
ZAP1 
MAR  
 
MAR  
 
inactive 
ARTD and Zinc-fingers and WWE 
 
ARTD and Zinc-fingers and WWE 
 
Zinc-fingers and WWE 
 
YES 
 
YES 
 
YES 
Tankyrase PARP5A 
  
PARP5B  
 
ARTD5, 
tankyrase 1 
ARTD6, 
tankyrase 2, 
PARP6* 
PAR  
 
PAR  
 
ARTD and Ankyrin repeat 
 
ARTD and Ankyrin repeat 
YES 
 
YES 
MacroPARP PARP9  
 
PARP14  
 
PARP15  
 
ARTD9, 
BAL1 
ARTD8, 
BAL2, 
COAST6 
ARTD7, 
BAL3 
inactive 
 
MAR  
 
MAR  
 
Macrodomain 
 
ARTD, Macrodomain and WWE 
 
ARTD and Macrodomain 
YES 
 
YES 
 
YES 
 PARP4  
 
ARTD4, 
vPARP 
PAR  
 
ARTD and BRCT NO 
 PARP6* ARTD17 MAR  ARTD  NO 
 PARP8  ARTD16 MAR  ARTD NO 
 PARP10  ARTD10 MAR  ARTD NO 
 PARP11  ARTD11 MAR  WWE NO 
 PARP16 ARTD15 MAR ARTD YES 
ADP-ribosyl transferase (ATRD); B-aggressive lymphoma protein (BAL); Collaborator of signal transducer and activator of transcription 6 (COAST6); vault 
PARP (vPARP); zinc-finger antiviral protein 1 (ZAP1); zinc-finger CCH-type antiviral protein 1 (ZC3HAV1); zinc-finger CCH domain-containing protein 1 
(ZC3HDC1). Enzymatic activity: mono- (MAR), or poly- (PAR)[1, 3] *PARP6 which refers to two different proteins. 
 
1.3. PARP14 structure 
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PARP14 contains three macrodomains (Macro1-3), a WWE 
domain and a catalytic domain, (Fig. (1)) [9, 10]. PARP14, 
like PARP10, contains RNA recognition motif (RRM) 
domains. The PARP14 Macrodomains are ADPr-binding 
modules that do not have allosteric contact with one another 
[9]. Each tightly packed domain is supported by a seven-
stranded β-sheet with two or three α-helixes on each side. 
Macro1 binds ADPr with low affinity whereas Macro2 and 
Macro3 bind ADPr with high affinity. The Macro2 and 
Macro3 of PARP14 only interact with MARylated but not 
PARylated substrates, thus can distinguish between MAR and 
PAR as shown by the macrodomains detecting PARP10-
dependant MARylated substrates both in vitro and in cells [9]. 
Therefore, not only is PARP14 able to act as a post-
translational modifier through its catalytic domain, but also as 
a modification reader through its unique macrodomain. 
Containing the conserved Trp (W) and Glu (E) residues, the 
WWE domain stabilizes the protein structure, and preferably 
binds to ADPr derivatives. A possible enzymatic target for the 
WWE domain has been suggested since mono ADPr binds 
preferentially over iso ADPr moieties [11]. 
The catalytic domain contains a NAD+ binding pocket, or 
catalytic site, that is made up of a “base”, “walls” and a “lid”. 
The base is formed by β-sheet 3 and a loop connecting α-helix 
3. The walls are formed by β-sheet 4 and α-helix 4. The lid is 
formed by a loop between α-helix 3 and β-sheet 4 (called the 
D-loop 1622-1626) [11]. Key binding residues in the catalytic 
site include: hydrogen bonding residue Asp1604; aromatic 
residues Tyr1633 and Tyr1646; along with other residues, 
such as His1601, Gly1602, Thr1603, Ser1607, Ser1641 and 
Thr1645. Outside of the catalytic site, Tyr 1620 is a key 
aromatic residue [11]. Another site that is located within the 
catalytic domain is the adenosine subsite. Key binding 
residues in the adenosine subsite include: hydrogen bonding 
residue Ser1722; Aromatic residues Tyr1727 and Tyr1714; 
along with other residues, such as Gly1683. 
 
  
Fig. (1). Schematic representation of the PARP14 domain 
architecture [9, 12]. 
 
2. PARP14  
2.1. Known Function 
PARP14 is the largest PARP enzyme, containing 1,801 amino 
acids, including those that form the characteristic 
macrodomain folds of the macroPARP subfamily [3]. The 
macrodomain folds are ADPr-binding modules that facilitate 
the localisation of macroPARPs for MARylation [3]. 
Homologous to the human BAL2b, a member of the B 
aggressive lymphoma family (BAL), PARP14 functions as a 
protective mediator in B cells. Expression of PARP14 enables 
the cell to avoid apoptosis and increase rate of B cell 
differentiation [13]. 
 
2.1.1 STAT6 Activation  
As its alias Collaborator of signal transducer and activator of 
transcription 6 (CoaSt6) entails, PARP14 is crucial for the 
activation and activity of the signal transducer and activator 
of transcription factor 6 (STAT6), a protein which promotes 
the proliferation and differentiation of CD4+ T-helper 2 (Th2) 
cells [14, 15]. The initial activation of STAT6 by the janus 
kinase mediated tyrosine phosphorylation (JAK/STAT) 
pathway, is promoted by PARP14 [16]. The phosphorylation 
process is initiated by the extracellular cytokine interleukin-4 
(IL-4), which binds to the N-P-X-Y tyrosine residue on the 
JAK receptor along with an unphosphorylated STAT6 
molecule. The binding of both substrates gives the activated 
complex, phosphorylating STAT6, which then dimerises and 
translocates to the nucleus [13, 16, 17]. However, this 
pathway is inhibited by the genes suppressor of cytokine 
signaling 1 (SOCS1) and SOCS2, which are stimulated in 
response to cytokines secreted by Th1 cells (IL-6, IL-10 and 
interferon-gamma). PARP14’s MARylation of the SOCSs 
genes inactivates their expression, thereby ensuring the 
continual activation of STAT6 [14]. 
PARP14’s involvement in the functional capacity of STAT6 
occurs within the nucleus, and acts to provide STAT6 with 
access to the promoter region of the trans-acting T-cell-
specific transcription factor (GATA3). In the absence of 
PARP14, histone deacetylase complex 2 (HDAC2) and 
HDAC3 bind to the promoter region of GATA3, preventing 
its expression [18]. PARP14 catalysed MARylation of these 
complexes causing HDAC2 and HDAC3 to disassociate from 
the gene, allowing STAT6 to bind to the palindromic 5’-
TTC…GGA-3’ repeat site, and activate transcription of the 
gene [15, 18, 19]. It is seen that in the absence of PARP14, 
STAT6 mediated signaling was notably impaired due to its 
interactions at both the activation and function of the 
transcription factor [14, 17, 18]. 
 
2.1.2 B Cell Differentiation  
As a result of PARP14s involvement in STAT6 activation, 
and consequential expression of GATA3, it is evident that the 
enzyme plays a crucial role in Th2 differentiation [20-22].  
Furthermore, using murine models, it is suggested that 
PARP14 promotes the upregulation of 2,314 B cell genes 
involved in glycolysis, and/or mitochondrial activity, thereby 
presenting PARP14 as a key mediator of B cell metabolic 
fitness, maturation and survival [14]. 
PARP14’s influence on the upregulation of these metabolic 
and survival genes promotes the release of Th2 cell major 
cytokines, IL-4, IL-13 and IL-10, thereby promoting the 
humoral (type II) immune response. IL-4’s endogenous effect 
on T-cells causes the differentiation into Th2 cells to be 
favored, via activation of the JAK/STAT pathway and 
amplification of its own expression [18]. IL-4 also activates 
the Akt signaling pathway, which involves the activation or 
inhibition of numerous genes, resulting in the enhancement of 
cell cycle progression, glucose metabolism, and cell growth, 
whilst suppressing apoptosis [16]. Furthermore, IL-4 activates 
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the immunoglobulin class switching of B cells towards the 
production of IgE and IgG1, promoting the inflammatory 
response [23]. Studies have noted that PARP14 is directly 
required to achieve maximum IL-4 induced B cell pro-
survival signaling [18, 24]. Effects of activating the release of 
IL-13 are similar to that of IL-4, as both interleukins activate 
the IL-4 R alpha binding subunit. However, IL-13 also 
stimulates the genes for the mitogen-activated protein kinases 
ERK1 and ERK2, which promote cell survival, differentiation 
and metabolism [25]. 
 
2.1.3 JNK1/JNK2 Signaling Pathway 
JNK signalling has a well-established role in apoptosis, cell 
proliferation, transformation and survival, via substrate 
phosphorylation [26]. The isoforms, JNK1 and JNK2 are 
ubiquitously expressed and considered redundant kinases [26, 
27]. JNK2 is associated with various human cancers, often 
proving an essential enzyme in the growth of lung 
glioblastoma, skin and prostate cancer [26]. JNK2 regulates 
the cytoplasmic PARP14, which binds to and suppresses 
JNK1 activity when tested under physiological conditions 
[26]. Overexpression of PARP14 is noted to completely 
suppress JNK1 activity. Studies which deplete endogenous 
JNK2 display an enhanced rate of apoptosis in multiple 
myeloma cell lines, however, by inducing PARP14 
expression, the enhanced apoptosis was completely reversed, 
and JNK1 expression restored [26]. Furthermore, through 
overexpression of PARP14 and the consequential suppression 
of JNK1, the M2 isoform of pyruvate kinase (PKM2) 
expression levels increase [27]. In its tetrameric form, PKM2 
catalyses the rapid conversion of phosphoenolpyruvate (PEP) 
and ADP to pyruvate and ATP (Fig. (2)) [28]. Actively 
dividing cells (including cancers) predominantly express the 
PKM2 isoform in order to facilitate their high demand for 
ATP [28, 29].  The dimerized isomer of PKM2 acts as a 
nuclear kinase, translocating to the nucleus where it activiates 
a number of genes, including c-Myc and and hypoxia-
inducible factor 1α [30]. Thus, PARP14 has a role in 
improving the glycolytic fitness of cancer cells. Both in vitro 
and in vivo analyses of c-Myc-driven burkitt lymphoma and 
multiple myelomas show that PARP14 expression is a critical 
mediator of cell survival [13, 16, 26, 31]. 
 
 
2.1.4 Interactions with PGI/AMF Complex  
PARP14 MARylation of the protein autocrine motility 
factor/phosphoglucose isomerase (AMF/PGI) complex 
activates the dual functioning protein, causing upregulation of 
cellular energy production and survival [16].  Acting as an 
extracellular cytokine, AMF stimulates the Akt cell signaling 
pathway, whilst its role as the glycolic enzyme (PGI) converts 
glucose-6-phosphate to fructose-6-phosphate- a step 
preceding ATP generation, thereby promoting the energy 
production [15]. 
 
2.1.5 Homologous recombination  
Like the DNA-dependent PARPs, PARP14 plays a role in 
DNA repair, by way of homologous recombination (HR). It 
has recently been suggested that PARP14 induced 
MARylation of the specialised DNA polymerases is required 
for HR, as both tissue and murine models demonstrate that in 
the absence of PARP14, HR can be initiated, but not 
completed [12]. It is suggested that PARP14 is involved in the 
strand invasion step, enabling the D-loop extension of the 
RAD51 foci by MARylating the RAD51 gene [12]. 
 
2.2. PARP14 as a potential anti-cancer target 
Cancer cells require a large amount of energy to sustain their 
rapid growth, as well as cellular adaptations to prevent 
apoptotic mechanisms, which would prevent growth. This is 
partially facilitated by a sophistication in cellular metabolism 
from aerobic to anaerobic (regardless of oxygen availability), 
known as the Warburg effect [31]. Evidence suggests that the 
Warburg effect is the result of the over-activation of pro-
survival signaling pathways, many of which, including HIF-
1α and cMyc, are induced by PARP14 activation [32]. 
PARP14’s interaction with promoting the growth of Th2 cells, 
inhibiting apoptotic pathways and increasing the 
inflammatory response can all be seen in association with 
promoting the progression of cancer. This has been 
demonstrated in hepatocellular carcinoma (HCC) cells; 
PARP14 levels are increased in cancer cells when compared 
to normal, healthy cells [27]. When the PARP14 protein was 
inhibited (using a shRNA knockdown model) the cancer cells 
had a significantly slower rate of growth while the normal 
cells growth rate was not affected, posing a PARP14 inhibitor 
as a method to selectively target cancer cells over normal cells 
[15]. 
 
2.3. PARP14 as a potential anti-inflammatory target 
PARP14’s role in promoting the differentiation of Th2 cells 
has sparked interest as to its association with the inflammatory 
response, and immune regulation [19]. Through transgenetic 
mice models, it has been observed that STAT6 overactivation, 
and consequential hyper-Th2 environment predisposes mice 
to develop allergic inflammation [33]. Many inflammatory 
disorders, including eosinophilic esophagitis (EoE), atopic 
dermatitis (AD), asthma-related phenotypes of airway hyper 
responsiveness (AHR) and food allergies are characterised by 
an overactivation of STAT6 and an increase in Th2 cytokines 
[34, 35]. Due to PARP14’s role in promoting the activation of 
STAT6, it is seen that inhibition of PAPR14 in EoE models 
can reduce inflammation and restore lung function [17]. 
Studies have also noted a positive correlation between 
PARP14 and expression of eotaxin-3 (CCL26), an eosinophil 
chemoattractant responsible for the increased eosinophil 
infiltration observed in EoE, and likewise, inhibition of 
PARP14 decreased CCL26 expression [24]. Therefore, the 
critical role in which PARP14 plays in the STAT6 mediated 
activation of Th2, and release of Th2 cytokines, present an 
opportunity to inhibit PARP14 in order to decrease hyper 
inflammation in conditions such as EoE [33]. However, a 
2015 study contradicts these claims, suggesting that 
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PARP14’s involvement in hyper allergic diseases is in fact 
part of the immune defense system, and silencing of the 
PARP14 gene accelerates the progression of such states [36]. 
PARP14 has been noted to increase the M1 macrophage 
phenotype, and anti-inflammatory immune response that 
counters the M2 proinflammation [36]. Observations of 
allergic skin inflammation correlates silencing of the PARP14 
gene with an acceleration of disease progression due to the 
decrease of B cells, as a result of the attenuation of PARP14’s 
B cell survival signaling [36]. Other conditions such as acute 
arterial lesions and chronic atherosclerosis show similar 
disease-accelerating patterns [36]. Therefore, the question as 
to whether PARP14 promotes the development of 
hyperallergic diseases through its promotion of a Th2 
dominant environment, or if the activation of haematopoietic 
cell survival pathways assists the immune system in fighting 
allergic diseases is up for debate, and successful synthesis of 
a selective PARP14 inhibitor could be key to answering some 
of these questions.  
 
 
Fig. (2). Summary of PARP14’s interactions with STAT6 
induced activation of GATA3. PARP14 mediated 
MARylation of HDAC2 and HDAC3 cause the complexes to 
disassociate from the GATA3 promotor region allowing 
STAT6 to bind to the 5’-TCCNNNNGGA-3’ repeat. PARP14 
further inhibiting the expression of the suppressor of cytokine 
signaling genes (SOCS1 and SOCS2).  
 
 
3.1 PARP Inhibitors 
The first general PARP inhibitors (substituted benzamides) 
were identified in 1980. With the exception of coumarine and 
indole derivatives, which have been suggested to bind to one 
of the zinc finger domains, all known PARP inhibitors are 
nicotinamide mimetics that bind in the NAD+ binding pocket 
of the catalytic domain as a competitive inhibitor [14]. PARP1 
is the most active target of drug discovery and it is likely that 
these inhibitors are not selective to PARP1 over the other 
family members. The first PARP inhibitor Lynparza (also 
known as olaparib (AZD2281) KuDOS Pharmaceuticals and 
AstraZenca) was approved by many regulatory bodies 
worldwide in 2014 for the treatment of ovarian, fallopian tube 
and primary peritoneal cancer in women who have BRCA1 or 
BRCA2 mutations and have received three or more 
chemotherapy treatments. Lynparza is an oral PARP inhibitor 
with an IC50 of 2.9nM for PARP1 [37]. Lynparza also binds 
strongly to PARPs2-4 and weakly to PARP12, PARP15 and 
PARP16 [11]. Rucaparib (Clovis Oncolocy Inc.) is also an 
oral PARP1, PARP2 and PARP3 inhibitor being developed 
for advanced ovarian and metastatic castration-resistant 
prostate cancer.  
 
3.2 Current status of PARP inhibitors and its shortcomings 
Current PARP inhibitors, Lynparza and Rucaparib, work on 
the basis of synthetic lethality, targeting the DNA-repair 
PARPs which have a clearly established role in base excision 
repair and single stranded break repair. As the BRCA 
mutation prevents cells from completing HR, inhibition of the 
PARPs completely abolishes the cell’s ability to repair DNA, 
thereby generating a lethality towards BRCA mutated cells 
over non-mutated cells [38]. They further act as 
chemosensitizers (reducing the apoptotic threshold) when 
combined with DNA damaging agents such as temozolomide 
or cisplatin [37].  The shortcomings of the current PARP 
inhibitors are that they only traget breast cancer patients with 
specific BRCA mutations. This makes their use limited to a 
small proportion of the population. There is a need for cancer 
treatments that can target a broader range of cancer types, for 
example, metastatic cancers. PARP14 has been shown to 
affect the ability for these cancer cells to grow and become 
metastatic, therefore targeting PARP14 may enable the 
treatment of a broader range of cancers. 
  
3.3. Known inhibitors for PARP14 
Recent knowledge about the structure and function of 
PARP14 has it identified as a possible anti-cancer and anti-
inflammatory target. Although there is a great deal of 
structural similarity between the catalytic domain of different 
PARPs, there is scarce structural information on PARP14 
inhibitors. PARP inhibitors to date are mostly non-selective 
inhibitors and tend to inhibit multiple PARPs. There is no 
evidence indicating whether selective or non-selective PARP 
inhibitors are more advantageous for treating disease, 
although highly selective PARP inhibitors have not yet been 
reported. 
 
3.3.1 Unselective inhibitors 
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The first reported PARP14 inhibitors were published as part 
of a family-wide chemical profiling paper on PARPs [11]. 
This work identified inhibitors, computationally, as being 
either selective to PARPs1-4 or non-selective. Fig. (3) shows 
the non-selective PARP inhibitors that had favorable binding 
to PARP proteins, including PARP14. Investigation of 
compounds 1, 2, 3, and 5 with PARP14 indicated key 
hydrophobic interactions with residues Tyr1633, Tyr1624, 
Tyr1640 and Tyr1646 and hydrogen bonding residues, 
Ser1641 and Gly1602 [11]. These non-selective inhibitors 
have no reported inhibition data with PARP14. 
Fig. (3). Chemical structures of compounds 1 to 7 published 
with unselective PARP inhibition.  
 
Crystal structures of 1 with PARP14 show a key hydrophobic 
interaction with Tyr1633 and hydrogen bonding interaction 
with Ser1641 (3GOY.pdb and 3SE2.pdb). Compound 2 with 
PARP14 also demonstrates key hydrophobic interactions with 
Tyr1624, Tyr1633, Tyr1640 and Tyr1646 and hydrogen 
bonding with Gly1602 and Ser1641 (3SE2.pdb). A crystal 
structure of 3 with PARP14 indicated a unique hydrophobic 
interaction at the opening of the pocket with Tyr1620. Other 
interactions include hydrophobic interactions with Tyr1620, 
Tyr1633, Tyr1646 and hydrogen bonding with Gly1602 and 
Ser1641 (3SMI.pdb). Another crystal structure from this set 
of compounds was compound 5 with PARP14. The key 
interactions include hydrophobic interactions with Tyr1633, 
Tyr1640 and Tyr1646 and hydrogen bonding with Gly1602 
and Ser1641 (3SMJ.pdb) [11]. 
 
3.3.2 General PARP14 inhibitors  
Benzothiazoles 8-11 are potent inhibitors of PARP14 showing 
µM inhibition (Fig. (4)). There is no information on selectivity 
or inhibition of other PARP enzymes with these compounds. 
The crystal structure of PARP14 with 11 shows key 
hydrophobic binding interactions with Tyr1714 and Tyr1727, 
and hydrogen bonding with Ser1722. No interactions were 
observed with Tyr1620 (4PY4.pdb) [39]. 
 
 
Fig. (4). Chemical structures of compounds 8 to 11 published 
with no selectivity information against PARP superfamily. 
IC50 values are shown next to the compounds.  
 
3.3.3 Structural Activity Studies of PARP14 inhibitors  
Work reporting PARP14 inhibitors as a virtual screening 
library identified two main inhibitors of PARP14, 12 and 13 
(Fig. (5)) [19]. The second generation library, from this group, 
were synthesized and gave more structural insight into how to 
selectively target PARP1, PARP10, PARP14 and PARP15. 
This work demonstrated that placing the anilide moiety in 
para-position on the benzamide region, or alkylating the 
benzamide, proved detrimental to enzyme inhibition in all 
PARPs tested.  Minor preference for PARP14 was shown 
when a methyl-ester group was present as in compound 25 
(Fig. (5)) [40].
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Fig. (5). Chemical structures of compounds 12 to 26 that search for selectivity against PARP superfamily. IC50 values are shown 
next to the compounds.  
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A crystal structure of compound 12 bound in the catalytic 
domain of PARP14 shows key binding interactions with 
Tyr1633, Tyr1640, Tyr1646 and hydrogen bonding with 
Gly1602 and Ser1641(4F1Q.pdb). Similarly, compound 13 
showed hydrophobic interactions with Tyr1633, Tyr1640 and 
Tyr1646 and hydrogen bonding with Gly1602, Asn1624, 
Tyr1640 and Ser1641 (4F1L.pdb). Again no interactions were 
observed with Tyr1620 [19]. 
Peng et al. have published a high-throughput synthesis and 
screening of >1000 compounds using a small molecule 
microarray based strategy. The compounds were bidentate 
inhibitors which bound to both the primary pocket (catalytic 
site) and secondary pocket (adenosine binding subsite) in 
PARP14. This method identified 27 a potent PARP14 
inhibitor that is 20 times more selective for PARP14 over 
PARP1 (Fig. (6)) [41].  Two other potent inhibitors were 
identified, 28 and 29, which were less selective over the other 
PARP enzymes. A crystal structure of 27 bound in the 
catalytic domain of PARP14 shows key binding interactions 
with Thr1713 and Phe1697 and hydrogen bonding with 
Thr1684. Secondary binding was observed between the 
benzamide group and adenosine subsite residues Tyr1727, 
Tyr1714 and Tyr1721 and hydrogen bonding with Asn1698 
(5LYH.pdb). A crystal structure of 28 showed similar 
interactions with the benzamide group and adenosine subsite 
residues Tyr1721, Tyr1727, Tyr1721 and Tyr1714 as well as 
hydrogen bonding with Gly1683 and Ser1722. The other end 
of 28 interacted with Tyr1726 (5LXP.pdb). 
Yoneyama-Hirozane et al. have identified PARP14 inhibitors 
using a novel auto-ribosylation method. They screened a 
diverse library of approximately 500,000 small compounds 
from a library at Takede Pharmaceutical Company. Two 
compounds 30 and 31 were identified as potent inhibitors with 
a high degree of selectivity over PARP1 (Fig. (6)). The crystal 
structures of these two compounds both show interactions 
with the adenosine subsite residues Tyr1727 and hydrogen 
bonding between Ser1722 and Gly1683 (5V7T.pdb and 
5V7W.pdb). Compounds 31 also has additional interactions 
with Tyr1714 (5V7W.pdb) [42]. Neither of these compounds 
bound to the catalytic site only the adenosine subsite. 
Upton et al. have also targeted both the catalytic site and 
adenosine binding subsite in PARP14 hoping to achieve 
selectivity for PARP14 over the other PARP enzymes. They 
have produced 3 generations of inhibitors, each generation 
giving further SAR information and increasing in potency. 
Generation 3 piperazinyl-amide derivatives 32-37 display 
poor selectivity for PARP14 over PARP1 and PARP5a but are 
highly potent with 32 being the most potent PARP14 inhibitor 
to date (Fig. (6)).  
Compounds 33-35 all displayed potency below 1 µM (Fig. 
(6)). Activity was lost when a heteroaryl group was added to 
the piperazine ring as shown with 36. Also, addition of 
another aromatic ring as in compound 37 decreased the 
effectiveness of the inhibitor [43]. A crystal structure of 35 
shows the aminobenzamide moiety bound into the 
nicotinamide pocket with interactions between the fluorinated 
aryl ring and Leu1755, Val1773, Val1784 and Leu1782 
(5NEQ.pdb). 
 
3.3. Possible Future Strategies for Designing Selective 
PARP14 Inhibitors 
Comparison of the catalytic site of PARP14 with the other 
PARPs (PARPs1-4, PARP5a, PARP5b, PARPs9-10, 
PARPs12-16) showed that the “base” of the pocket is highly 
conserved [11]. Greater sequence variability is shown on the 
outer edges of the catalytic site, in particular, the D-loop [11]. 
The D-loop of PARP14 has a great deal of plasticity when 
compared to the longer more rigid D-loops in PARP1 and 
PARP2. This variability of the D-loops between the different 
PARPs could lead us to developing selective PARP inhibitors. 
PARP14 also presents a Tyr1620 residue in the D-loop region 
that is unique and not observed in other PARPs that were 
investigated [11]. Although this research did not investigate 
PARP7, PARP6, PARP8 and PARP10 due to the 
unavailability of crystal structures, it is clear that targeting the 
catalytic site may prove difficult. Within the catalytic domain 
there is a secondary binding site known as the adenosine 
subsite. When NAD+ (nicotinamide adenine dinucleotide) 
binds to the catalytic domain the nicotinamide moiety binds 
into the catalytic site and the adenine moiety binds into the 
adenosine subsite. The adenine subsite is less conserved 
across the PARP superfamily members and compounds that 
are large and can bind to both of these sites within the catalytic 
domain may lead to designing selective PARP14 inhibitors 
[11]. 
Another possible way to selectively inhibit PARP14 over the 
other PARPs is to target the macrodomains. The macroPARPs 
(PARP9, PARP14 and PARP15) all contain macrodomains 
with PARP14 and PARP15 displaying mono(ADP-ribosyl) 
transferases (MARs) activity while PARP9 is inactive. 
PARP15 has two macrodomains and PARP14 has three 
macrodomains. The two PARPs have 72% identity when 
comparing the homology of their PARP catalytic sites which 
can be related to their evolutionary relationship [44]. 
Comparison of the PARP14 Macro1, Macro2 and Macro3 
domains with PARP15 Macro1 and Macro2 domains show 
between 24.4% and 60.8% identity, with the most identity 
between PARP14 Macro3 and PARP15 Macro2. PARP14 
Macro 3 has been shown to bind strongly to ADPr [44]. 
Homology modeling shows that ADPr based inhibitors may 
possibly target the macrodomains. 
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Fig. (6). Chemical structures of compounds 27 to 31 that search for selectivity against PARP superfamily. IC50 values are shown 
next to the compounds.  
 
O
NH2 H
N
O
N
H
O
N
NN
HN
S
O
O
HO
O
27
PARP14 = 0.49 µM
PARP1 
 = 11.68 µM
PARP5a = 9.04 µM
O
NH2 H
N
O
H
N
O
N
NN
28 PARP14 = 0.76 µM
PARP1 
  = 4.66 µM
PARP5a = 3.03 µM
O
NH2 H
N
O
29
PARP14 = 0.77 µM
PARP1 
  = 9.50 µM
PARP5a = 17.08 µM
O
N
H
N
H
HN O
S
O
O
O2N
30 PARP14 = 0.58 µM
PARP1 
  = >30 µM
O
N O N
N
N
N
31 PARP14 = 0.31 
µM
PARP1 
  = 26 µM
S
N
NH
O
NH
N
NH2O
N
H
O
O
N
N N
N
36 PARP14 = 2.8 µM
NH2O
N
H
O
O
N
N
F
35 PARP14 = 0.70 
µM
PARP1 
  = 0.56 µM
PARP5a = 2.7 µM
NH2O
N
H
O
O
N
N
37 PARP14 = 4.2 
µM
PARP1 
  = 0.8 µM
PARP5a = 9.8 µM
NH2O
N
H
O
O
N
N
Cl
32 PARP14 = 0.16 
µM
PARP1 
  = 0.22 µM
PARP5a = 0.90 µM
NH2O
N
H
O
O
N
N O
O
33 PARP14 = 0.37 µM
NH2O
N
H
O
O
N
N
34 PARP14 = 0.90 
µM
PARP1 
  = 0.37 µM
PARP5a = 6.0 µM
10     Schweiker et al. 
The possibility of targeting the WWE domain is another 
option with WWE domains being present in PARP7, 
PARP11, PARP12, PARP13 and PARP14. The WWE 
domains of PARP11 and PARP14 have been shown to bind 
ADPr derivatives including, ATP and ADPr for PARP11, and 
ADPr only for PARP14 [45, 46]. Although there is no 
information on inhibition of the PARPs upon binding of these 
compounds, it can be concluded that ADPr based inhibitors 
may also bind well to the WWE domain.  
 
5 CONCLUSION 
PARP14 has been identified as a promising anti-cancer and 
anti-inflammatory target. Acting as a transcriptional co-
activator for STAT6, PARP14 acts to promote the over 
activation of the Th2 immune response, thus promoting a 
metabolic change to an anaerobic state (Warburg effect) and 
activation of cell survival pathways through JNK2 and the 
PGI/AMF complex. These changes are consistent with the 
metabolic sophistication observed in cancer, and the immune 
imbalance in inflammatory diseases. Thus, designing 
PARP14 inhibitors represents a new area of research, with 
PARP14 recently identified as a possible anti-cancer and anti-
inflammatory target. Current literature on PARP14 inhibition 
shows that designing a selective inhibitor could be possible, 
although there is yet no solid evidence that selective PARP 
inhibitors would be advantageous for treating any diseased 
state. The high conservation of the catalytic domain makes the 
possibility of designing inhibitors that are selective for 
PARP14 over the other 17 PARP family members 
challenging, unless targeting a unique residue within this 
domain that is outside of the catalytic binding site. We suggest 
that targeting the macrodomain and WWE domain may 
provide another option for producing selective inhibitors. One 
possible scaffold for targeting these domains could be 
derivatives of ADPr, representing a novel option for future 
design.  
 
LIST OF ABBREVIATIONS 
AD  Atopic dermatitis 
ADPr   ADP-ribose  
AHR  Airway hyper responsiveness 
Akt                       Protein Kinase B 
A-ribose  Adenine-proximal ribose  
AMF/PGI  Autocrine motility factor/phosphoglucose 
isomerase 
ARTD  ADP-ribosyl transferase 
BRCA1                Breast Cancer 1 
BRCA2                Breast Cancer 2 
BAL   B-aggressive lymphoma protein  
COAST6  Collaborator of signal transducer and 
activator of transcription 6 
EoE  Eosinophilic esophagitis 
ERK1  Mitogen-activated protein kinase 1 
ERK2  Mitogen-activated protein kinase 2 
HCC   Hepatocellular carcinoma 
HDAC2  Histone deacetylase complex 2  
HDAC3  Histone deacetylase complex 3 
HR   Homologous recombination  
IL-4  Cytokine interleukin-4  
JNK1  Kinase Jun N-terminal kinase 1 
JAK/STAT  Janus kinase mediated tyrosine 
phosphorylation pathway 
MAPK  Mitogen activated protein kinases  
MAR  Mono(ADP-ribosyl) transferase 
MARylation  Mono(ADP-ribosyl)ation  
N-ribose  Nicotinamide-proximal ribose  
PARP14  Poly(ADP-ribose)polymerase, member 14 
PAR  Poly (ADP- ribosyl) transferase 
PARylation  Poly(ADP-ribosyl)ation  
PEP  Phosphoenolpyruvate  
PKM2  Pyruvate kinase isoform M2 
SOCS1   Suppressor of cytokine signaling 1  
SOCS2  Suppressor of cytokine signaling 2 
Th2  T-helper 2 
UPR  Unfolded Protein Response 
vPARP   Vault PARP 
ZAP1   Zinc-finger antiviral protein 1 
ZC3HAV1  Zinc-finger CCH-type antiviral protein 1 
ZC3HDC1  Zinc-finger CCH domain-containing 
protein 1 
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